Search

everythinglearnresearchcommunity

for

Search:↓

The user has been taking 2.5 mg of dutasteride for 6 months and using minoxidil topically for 3 years but hasn't seen significant hair regrowth, only a slight decrease in hair loss. Suggestions include switching to oral minoxidil, adding microneedling, or using growth agonists like bimatoprost to improve results.

The user used finasteride but stopped due to side effects, then used topical minoxidil for 13 months, and later added KX826/pyrilutamide for 8 months. They experienced shedding after starting pyrilutamide and use minoxidil and KX826 once daily.

A 26-year-old is experiencing worsening hair thinning despite using dutasteride 0.5 mg and oral minoxidil 5 mg, alongside ketoconazole for seborrheic dermatitis. Users suggest patience, as results may take 12–18 months, and consider increasing the dutasteride dosage or consulting a dermatologist.

The user reported significant hair regrowth after 2.5 months using 2.5 mg oral Minoxidil daily and 0.5 mg Dutasteride three times a week, along with betamethasone for scalp inflammation. They experienced minor side effects and are considering microneedling.

Pyrilutamide's effectiveness is questioned due to overstated claims and previous trial ineffectiveness, with some users opting for finasteride instead. Despite skepticism, some consider adding pyrilutamide to their regimen alongside treatments like bicalutamide.

The user is taking 0.5mg finasteride and 0.5mg Loniten orally daily, using Eucapil twice weekly, and Minoxidil foam once daily for hair loss. They believe Eucapil effectively stops hair loss despite side effects like breast growth.

The user experiences an itchy scalp and finds relief using shampoo and Zyrtec, which helps with inflammation. They are unsure if the issue is related to histamines or seborrheic dermatitis.

The conversation discusses various hair loss treatments, including Breezula, KX826, and PP405, with mixed opinions on their effectiveness compared to finasteride and minoxidil. Some users express skepticism about the new treatments, while others remain hopeful about future developments.

Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.

The user has been using 1.25 mg of oral minoxidil and finasteride since September 2025 to address diffuse hair thinning, and is considering trying a new shampoo. Other users suggest increasing the minoxidil dose and trying dutasteride.

User shared 1-year progress on Fin 1 mg, switching to 0.4 mg Dut and oral 1.25 mg Min. Good results with Fin, biotin supplement, and biotin shampoo; trying Dut and oral Min for potential better results.

The user observed that stopping nicotine and caffeine improved their scalp health while using oral finasteride. However, relapsing with caffeine and nicotine caused scalp tightness and inflammation.

Mixing 1ml of topical Minoxidil and Pyrilutamide (2ml total) together in a container and applying immediately is being discussed. The concern is whether this method degrades or compromises the efficacy of either compound.

A 25-year-old male experienced hair loss after taking breaks from oral dutasteride and minoxidil, leading to concerns about losing progress. He is advised to remain consistent with his current regimen and avoid adding spironolactone.

A dermatologist recommended using topical Dutasteride (15%) once a week, alongside oral Finasteride and Minoxidil, to improve hair strength and response. The user is seeking experiences or evidence on the effectiveness of this high-concentration regimen.

Topical dutasteride may have limited absorption due to its higher molecular mass compared to finasteride, potentially affecting its efficacy in suppressing DHT locally. Microneedling might enhance dutasteride absorption, possibly offering stronger local DHT suppression with fewer systemic effects.

High dose topical Finasteride solutions are speculative and not proven more effective than low dose solutions. Users report varying results with different concentrations, with some preferring lower doses to minimize side effects.

The user experienced significant hair regrowth on temples and beard using a combination of Dutasteride, Tretinoin, and topical Minoxidil, but stopped oral Minoxidil due to heart pain. The user switched from Finasteride to Dutasteride due to aggressive hair loss.

A user is concerned about using Alpicort, which contains Prednisolone and Salicylic Acid, for male pattern baldness. They are unsure if it will help or worsen their condition and are seeking advice.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

The user is using oral and topical minoxidil, finasteride, dutasteride, and considering adding rosemary and pumpkin saw palmetto to their regimen. They report significant hair growth, especially with dutasteride, and are considering increasing their dose and adding RU58841.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The conversation is about adjusting the dosage of topical Finasteride to avoid side effects like chest pain and breast swelling. The user is considering reducing the concentration to 0.1% or trying microdosing with 0.01-0.025% for lower systemic effects.

The post and conversation are about using bimatoprost for hair regrowth, with the user seeking a higher concentration to enhance results. The user also discusses difficulties in sourcing the powder for personal use.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

The user experienced facial puffiness after switching from finasteride to dutasteride, which they believe is due to dutasteride. They are seeking advice on reversing this effect, considering factors like diet, exercise, and potential hormonal changes.

A user is trying fluridil/topilutamide for hair loss and experiencing side effects like pain in the testicles and genital discomfort. They previously had adverse effects with finasteride, dutasteride, and RU58841, and are considering other treatments like topical dutasteride and spironolactone for maintenance before a hair transplant.

. This user experienced positive results from using a combination of minoxidil and finasteride, with no reported side effects after two months. Others have also shared their experiences with both short-term and long-term use of finasteride.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

OP is considering making a 5% topical Clascoterone (Breezula) for hair loss, as they use Minoxidil but can't use Finasteride due to side effects. They seek advice on creating the topical safely, possibly with help from a trained chemist.